Olaparib

Drug Profile

Olaparib

Alternative Names: AZD 221; AZD-2281; KU-0059436; KU-59436; Lynparza

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KuDOS Pharmaceuticals
  • Developer AstraZeneca; Cancer Research UK; Dana-Farber Cancer Institute; Eli Lilly; European Network of Gynaecological Oncological Trial Groups; German Breast Group; M. D. Anderson Cancer Center; Massachusetts General Hospital; Merck & Co; Myriad Genetics; National Cancer Institute (USA); National Institute of Oncology; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University of Oxford; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phthalazines; Piperazines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Registered Fallopian tube cancer; Peritoneal cancer
  • Phase III Breast cancer; Pancreatic cancer; Prostate cancer
  • Phase II Gastric cancer; Solid tumours
  • Phase I/II Glioblastoma; Head and neck cancer; Small cell lung cancer
  • Phase 0 Endometrial cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 18 Sep 2017 University College plans a phase III trial for Ovarian cancer(Combination therapy, Second-line therapy or greater, Maintenance Therapy) (NCT03278717)
  • 17 Aug 2017 Registered for Fallopian tube cancer (Recurrent, Second-line therapy or greater, Monotherapy) in USA (PO, Tablet) (9221524; 9221535)
  • 17 Aug 2017 Registered for Ovarian cancer (Monotherapy, Second-line therapy or greater, Late-stage disease, Recurrent) in USA (PO, Tablet) (9221524; 9221535)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top